{
    "ticker": "IMVT",
    "name": "Immunovant, Inc.",
    "description": "Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with autoimmune diseases. Founded in 2018 and headquartered in New York City, Immunovant aims to improve the lives of individuals suffering from conditions that are often debilitating and difficult to treat. The company's lead product candidate, IMVT-1401, is an innovative monoclonal antibody designed to target and inhibit the activity of the neonatal Fc receptor (FcRn), with the goal of reducing the levels of pathogenic IgG antibodies that contribute to autoimmune diseases. Immunovant is conducting clinical trials to evaluate the safety and efficacy of IMVT-1401 in various autoimmune disorders, including myasthenia gravis and warm autoimmune hemolytic anemia. The company is committed to patient-centric research and is focused on developing therapies that not only address the underlying disease mechanisms but also enhance patients' quality of life. By leveraging cutting-edge science and a robust clinical development strategy, Immunovant is poised to make significant contributions to the field of immunology and the treatment of autoimmune diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2018",
    "website": "https://www.immunovant.com",
    "ceo": "Helen Thackray",
    "social_media": {
        "twitter": "https://twitter.com/Immunovant",
        "linkedin": "https://www.linkedin.com/company/immunovant/"
    },
    "investor_relations": "https://investors.immunovant.com",
    "key_executives": [
        {
            "name": "Helen Thackray",
            "position": "CEO"
        },
        {
            "name": "Jesse L. Houghton",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IMVT-1401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immunovant, Inc. | Innovating Autoimmune Disease Treatments",
        "meta_description": "Learn about Immunovant, Inc. and its focus on developing innovative therapies for autoimmune diseases. Explore our lead candidate, IMVT-1401, and our mission to improve patient lives.",
        "keywords": [
            "Immunovant",
            "Autoimmune Diseases",
            "Immunology",
            "Biopharmaceuticals",
            "IMVT-1401"
        ]
    },
    "faq": [
        {
            "question": "What is Immunovant known for?",
            "answer": "Immunovant is known for developing therapies targeting autoimmune diseases, particularly its lead candidate IMVT-1401."
        },
        {
            "question": "Who is the CEO of Immunovant?",
            "answer": "Helen Thackray is the CEO of Immunovant, Inc."
        },
        {
            "question": "Where is Immunovant headquartered?",
            "answer": "Immunovant is headquartered in New York City, New York, USA."
        },
        {
            "question": "What is IMVT-1401?",
            "answer": "IMVT-1401 is a monoclonal antibody targeting the neonatal Fc receptor (FcRn) aimed at treating autoimmune diseases."
        },
        {
            "question": "When was Immunovant founded?",
            "answer": "Immunovant was founded in 2018."
        }
    ],
    "competitors": [
        "RGEN",
        "VYGR",
        "SNY",
        "ABBV"
    ],
    "related_stocks": [
        "BMY",
        "AMGN",
        "GILD",
        "REGN"
    ]
}